Enliven Therapeutics (NASDAQ:ELVN) Stock Price Breaks Above Fifty Day Moving Average – What’s Next?

Enliven Therapeutics, Inc. (NASDAQ:ELVN) crossed above its fifty day moving average during trading on Friday. The stock has a fifty day moving average of $47.25 and traded as high as $49.66. Enliven Therapeutics shares last traded at $49.43, with a volume of 969,641 shares traded.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on the company. Mizuho lifted their price target on Enliven Therapeutics from $62.00 to $73.00 and gave the stock an “outperform” rating in a report on Tuesday, August 18th. The Goldman Sachs Group raised their price target on shares of Enliven Therapeutics from $67.00 to $80.00 and gave the stock a “buy” rating in a research note on Thursday, August 6th. HC Wainwright increased their price target on shares of Enliven Therapeutics from $65.00 to $73.00 and gave the stock a “buy” rating in a research note on Monday, October 19th. Zacks Research lowered shares of Enliven Therapeutics from a “hold” rating to a “strong sell” rating in a research report on Tuesday, October 13th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Enliven Therapeutics in a research note on Thursday, October 15th. Ten investment analysts have rated the stock with a Buy rating and two have given a Sell rating to the stock. According to MarketBeat, Enliven Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $75.44.

Enliven Therapeutics Price Performance

The company has a market cap of $3.62 billion, a PE ratio of -28.91 and a beta of 0.34. The company has a fifty day moving average price of $47.25 and a 200 day moving average price of $43.08.

Enliven Therapeutics (NASDAQ:ELVN) last posted its quarterly earnings data on Thursday, November 5th. The company reported ($0.36) EPS for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.09. As a group, sell-side analysts predict that Enliven Therapeutics, Inc. will post -1.79 EPS for the current fiscal year.

Insider Buying and Selling

In related news, Director J. Scott Garland sold 13,000 shares of Enliven Therapeutics stock in a transaction dated Thursday, October 1st. The stock was sold at an average price of $46.67, for a total value of $606,710.00. Following the completion of the transaction, the director directly owned 13,000 shares in the company, valued at approximately $606,710. This trade represents a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Benjamin Hohl sold 6,018 shares of the company’s stock in a transaction that occurred on Monday, October 19th. The stock was sold at an average price of $38.48, for a total value of $231,572.64. Following the sale, the chief financial officer owned 38,000 shares in the company, valued at approximately $1,462,240. This represents a 13.67% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 31,054 shares of company stock valued at $1,493,823. 3.00% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the stock. KBC Group NV purchased a new position in Enliven Therapeutics during the 1st quarter valued at $38,000. Three Bridge Wealth Advisors LLC bought a new position in shares of Enliven Therapeutics during the third quarter valued at $53,000. Sterling Capital Management LLC boosted its stake in Enliven Therapeutics by 1,180.7% in the 3rd quarter. Sterling Capital Management LLC now owns 1,921 shares of the company’s stock valued at $88,000 after purchasing an additional 1,771 shares during the period. State of Wyoming bought a new position in Enliven Therapeutics in the 2nd quarter valued at about $96,000. Finally, ProShare Advisors LLC increased its stake in shares of Enliven Therapeutics by 29.5% during the third quarter. ProShare Advisors LLC now owns 9,852 shares of the company’s stock valued at $452,000 after buying an additional 2,246 shares during the period. Institutional investors own 95.08% of the company’s stock.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing targeted therapies for patients with cancer. The company uses small-molecule drug discovery and development to pursue treatments designed to address validated cancer targets and improve patient outcomes.

Enliven’s pipeline includes ELVN-001, an investigational BCR-ABL1 tyrosine kinase inhibitor being developed for the treatment of chronic myeloid leukemia, and ELVN-002, an investigational HER2 inhibitor intended for use in patients with HER2-positive solid tumors.